AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
_06_23_2025_17_02_03_219040.jpg)
Highlights
Iofina PLC records its seventh straight year of increased revenue, led by growth in iodine derivatives.
Production capacity rises alongside consistent iodine pricing above key thresholds.
New plant development underway with completion expected in the third quarter of 2025.
Iofina PLC, listed on the London Stock Exchange (LSE:IOF) and also traded on the OTC markets (LSE:IOFNF), operates within the iodine production industry—a sector central to pharmaceuticals, medical imaging, nutrition, and high-tech manufacturing. As the global iodine market continues to respond to fluctuating demand and supply dynamics, the company maintains a steady course with infrastructure growth and consistent output. Iofina is a constituent of the FTSE AIM All-Share Index, reflecting its standing among growth-focused companies on the UK’s alternative investment market.
Revenue Momentum in Iodine Derivatives
Iofina PLC has maintained a pattern of year-on-year revenue growth, with iodine derivatives emerging as a primary contributor to this performance. The derivative segment experienced marked expansion, supported by wider industrial demand. Meanwhile, the crystallized iodine division preserved its previous revenue level, highlighting operational stability in a core business unit. These developments underpin a consistent revenue framework that reflects a balanced approach across product categories.
Enhanced Production Volumes
The company reported a notable increase in iodine production during the latest full-year period. Its production approach—rooted in extraction from brine streams through environmentally conscious methods—resulted in a double-digit rise in output volumes. The first quarter of the current calendar year showed continued production strength, with quarterly metrics pointing to sustained output levels through the mid-year period.
Pricing conditions have remained favourable, as iodine held at levels above key industry benchmarks per unit weight. This pricing consistency has provided a stable backdrop for revenue realization across the company’s segments.
Capital Deployment and Expansion Strategy
Iofina PLC concluded the prior year with a strong liquidity position and allocated capital toward operational growth. A significant portion of the expenditure was directed toward process enhancement and infrastructure development. These actions are aligned with the company’s broader focus on refining its iodine production platform and scaling its output capabilities.
Among its capital initiatives, Iofina invested in the advancement of plant technologies and optimisation of its existing processing facilities. These enhancements aim to improve yield efficiency and ensure resilience across its supply chain network.
Progress on New Facility Development
The company is currently progressing the construction of a new facility identified as IO#11. The plant, scheduled for operational readiness in the early second half of 2025, marks the latest step in Iofina’s plan to commission one new plant annually. The addition will be the eighth iodine processing facility under the IOsorb® model and the third facility added over a three-year span.
The new plant is expected to integrate into the company’s existing network, contributing to higher production throughput while supporting long-term strategic objectives. The continued rollout of facilities reflects Iofina’s emphasis on predictable growth through capital investment.
